title: Assessment of postischemic reperfusion and diamox activation test in stroke using 99mTc-ECD SPECT.
abstract: To evaluate the cerebral distribution of 99mTc-ethyl cysteinate dimer (99mTc-ECD) at blood flow levels beyond the normal range, we investigated postischemic reperfusion and acetazolamide (Diamox) activation test in stroke patients. The postischemic reperfusion was studied in 10 patients who showed a postischemic hyperperfusion area on other single photon emission computed tomography (SPECT) studies using N-isopropyl-rho-[123I]iodoamphetamine ([123I]IMP), 99mTc-hexamethyl propyleneamine oxime (99mTc-HMPAO), or 133Xe. 99mTc-ECD SPECT demonstrated a hyperactive area in one case, an isoactive area in four, and a hypoactive area in five. Correlations with CT findings revealed hyperactive areas without any abnormality, isoactive areas with perifocal rim, perifocal edema, or diffuse cerebral edema, and hypoactive areas with an infarct core. The Diamox activation test was studied in eight other patients with atherothrombotic stroke, and a limitation in vasodilative capacity was classified into three grades: Gr. 0 (none to minimal), Gr. I (mild), and Gr. II (moderate). [123I]IMP SPECT showed Gr. II and limitation in all eight cases. However, 99mTc-ECD showed Gr. II in three cases and Gr. I in five, and 99mTc-HMPAO revealed Gr. II in two cases, Gr. I in three, and Gr. 0 in three. We suggest that a lack of retention of 99mTc-ECD in a postischemic reperfusion area indicates the severity of the initial brain damage. Although the limitation in vasodilative capacity under Diamox-activated conditions was underestimated using 99mTc-labeled CBF tracers as compared with [123I]IMP, a retention of 99mTc-ECD in the unaffected area with an increased CBF under Diamox activation could be relatively superior to 99mTc-HMPAO.
authors.affiliation: Department of Neurosurgery and Radiology, Nakamura Memorial Hospital, Hokkaido Brain Research Foundation, Sapporo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Nakagawara
authors.forename: J
authors.initials: J
authors.lastname: Nakamura
authors.forename: R
authors.initials: R
authors.lastname: Takeda
authors.forename: T
authors.initials: T
authors.lastname: Okumura
authors.forename: T
authors.initials: T
authors.lastname: Seki
authors.forename: K
authors.initials: K
authors.lastname: Hayase
authors.forename: K
authors.initials: K
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Suematsu
mesh_terms: D000086:Acetazolamide; D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000175:diagnosis / Q000503:physiopathology*; D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000503:physiopathology*; D003545:Cysteine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D015424:Reperfusion; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D015609:Organotechnetium Compounds; C059659:technetium Tc 99m bicisate; D003545:Cysteine; D000086:Acetazolamide